Tute Genomics
Provider of a cloud-based SaaS platform and analytics services for whole-human genome analysis, variant annotation and interpretation, and genomics-focused machine-learning to support research, clinical sequencing workflows, and high-volume NGS testing.
Industries
Nr. of Employees
small (1-50)
Tute Genomics
Provo, Utah, United States, North America
Products
Cloud-based genome analysis platform
A cloud-hosted platform that performs whole-genome and genomic-panel analysis, including variant annotation and interpretation, for research and clinical use.
Cloud-based genome analysis platform
A cloud-hosted platform that performs whole-genome and genomic-panel analysis, including variant annotation and interpretation, for research and clinical use.
Services
Hands-on analytics and collaboration services for specialized genomics and bioinformatics projects.
Hands-on analytics and collaboration services for specialized genomics and bioinformatics projects.
Expertise Areas
- Cloud-based genome analytics
- Variant annotation and interpretation
- Phenotype-driven variant triage
- NGS informatics for high-volume clinical labs
Key Technologies
- Next-generation sequencing (NGS)
- Cloud-based analytics
- Variant annotation pipelines
- Genome interpretation algorithms
News & Updates
Announcement of a collaboration to provide informatics infrastructure to a high-volume newborn screening program to expand access to genomic medicine.
Webinar and discussion on using phenotype-driven variant triage to reduce NGS turnaround times and lower costs.
Announcement of the acquisition of genome interpretation assets to strengthen interpretation capabilities.
Company participation in conferences such as ACMG, AMP, and NSGC to present sequencing informatics and precision medicine topics.
Announcement of a collaboration to provide informatics infrastructure to a high-volume newborn screening program to expand access to genomic medicine.
Webinar and discussion on using phenotype-driven variant triage to reduce NGS turnaround times and lower costs.
Announcement of the acquisition of genome interpretation assets to strengthen interpretation capabilities.
Company participation in conferences such as ACMG, AMP, and NSGC to present sequencing informatics and precision medicine topics.